Piramal Pharma Limited (NSE:PPLPHARMA)
India
· Delayed Price · Currency is INR 179.85
-1.00 (-0.55%)
At close: Dec 5, 2025
Piramal Pharma Revenue
Piramal Pharma had revenue of 20.44B INR in the quarter ending September 30, 2025, a decrease of -8.83%. This brings the company's revenue in the last twelve months to 89.36B, up 2.66% year-over-year. In the fiscal year ending March 31, 2025, Piramal Pharma had annual revenue of 91.51B with 11.99% growth.
Revenue (ttm)
89.36B
Revenue Growth
+2.66%
P/S Ratio
2.67
Revenue / Employee
16.32M
Employees
5,476
Market Cap
238.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 91.51B | 9.80B | 11.99% |
| Mar 31, 2024 | 81.71B | 10.90B | 15.39% |
| Mar 31, 2023 | 70.82B | 3.47B | 5.16% |
| Mar 31, 2022 | 67.34B | 8.47B | 14.39% |
| Mar 31, 2021 | 58.87B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Divi's Laboratories | 100.29B |
| Cipla | 279.66B |
| Apollo Hospitals Enterprise | 232.65B |
| Zydus Lifesciences | 244.94B |
| Mankind Pharma | 135.46B |
| Aurobindo Pharma | 325.14B |
| Alkem Laboratories | 138.90B |